Article ; Online: Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.
Vascular health and risk management
2010 Volume 6, Page(s) 419–429
Abstract: Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, ... ...
| Abstract | Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary prophylaxis of such events and their complications. Because of the importance of platelets' involvement in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel--the current standard--has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Here, we review the main pathways through which platelets participate in acute thrombosis and the interruption of these pathways by using novel antiplatelet agents, including P2Y12 receptor antagonists (the recently approved prasugrel, the probable next-in-line ticagrelor, and others). The need for a more individualized patient therapy is evident; although most of the aforementioned pharmaceuticals have the potential to contribute to this, their clinical utility remains to be seen. |
|---|---|
| MeSH term(s) | Adenosine/adverse effects ; Adenosine/analogs & derivatives ; Adenosine/therapeutic use ; Animals ; Blood Platelets/drug effects ; Blood Platelets/metabolism ; Drugs, Investigational/adverse effects ; Drugs, Investigational/therapeutic use ; Humans ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Purinergic P2 Receptor Antagonists ; Receptors, Purinergic P2/blood ; Receptors, Purinergic P2Y12 ; Thrombosis/blood ; Thrombosis/drug therapy ; Thrombosis/etiology ; Ticagrelor ; Treatment Outcome |
| Chemical Substances | Drugs, Investigational ; P2RY12 protein, human ; Platelet Aggregation Inhibitors ; Purinergic P2 Receptor Antagonists ; Receptors, Purinergic P2 ; Receptors, Purinergic P2Y12 ; Ticagrelor (GLH0314RVC) ; Adenosine (K72T3FS567) |
| Language | English |
| Publishing date | 2010-06-01 |
| Publishing country | New Zealand |
| Document type | Journal Article ; Review |
| ZDB-ID | 2186568-1 |
| ISSN | 1178-2048 ; 1176-6344 |
| ISSN (online) | 1178-2048 |
| ISSN | 1176-6344 |
| DOI | 10.2147/vhrm.s7054 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6066: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.